ClinicalTrials.gg
CompletedNCT00141154Updated Mar 3, 2021

Comparison Of Celecoxib 200 Mg Bid, Loxoprofen Sodium 60 Mg Tid And Placebo In Low Back Pain In Japan

A Phase 3 interventional study of Celecoxib and Placebo in Low Back Pain, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 40 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-03-03.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,234
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Low Back Pain with a site in Japan — none open to participants now, none under way, none of them phase 3. Low Back Pain · Japan.

Enrollment
2nd of 13
1,234 · median 321
Started
2004
the only one that year
Phase 3
10 of 15
none open now
Registered
1st of 15
by date
Lead sponsor
2 of 15
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 15 studies in Low Back Pain with a site in Japan, this one is the 2nd largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2004, is one of 10 in phase 3, and was the 1st registered.

Low Back Pain

2,926 studies on the registry are indexed under Low Back Pain; 579 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

None of the 15 studies in Low Back Pain with a site in Japan is open now. The open studies under Low Back Pain, anywhere →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Low Back Pain with a site in Japan as a file.
02

Study summary

To verify the superiority of celecoxib (YM177) 200 mg bid to placebo in treatment of patients with low back pain as well as non-inferiority to loxoprofen sodium 60 mg tid.

03

Conditions studied

  • Low Back Pain

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have the major site of the low back pain at the 12th thoracic vertebra or lower
  • Patients who have had low back pain for at least two weeks

Exclusion criteria

Exclusion Criteria:

  • Patients who have a previous history or complication of rheumatoid arthritis, spondylarthrosis with negative serum reaction (ankylosing spondylarthritis, psoriatic arthritis), of tumor, Paget's disease, fibromyalgia, tumor or infection of spinal cord or intervertebral disc, or any other disease which can cause systemic pain
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
1,234 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Patient's pain assessment (VAS: Visual Analogue Scale)

Secondary outcomes

  1. Patient's global assessment (VAS), Physician's global assessment (VAS), Roland Morris Disability Questionnaire (RDQ)

07

Study locations

40 sites
  • Pfizer Investigational Site
    Funabashi-shi, Chiba, Japan
  • Pfizer Investigational Site
    Funabashi, Chiba 273-0035, Japan
  • Pfizer Investigational Site
    Matsudo-shi, Chiba, Japan
  • Pfizer Investigational Site
    Fukuoka-shi, Fukuoka, Japan
  • Pfizer Investigational Site
    Chitose, Hokkaido 066-0026, Japan
  • Pfizer Investigational Site
    Sapporo-shi, Hokkaido, Japan
  • Pfizer Investigational Site
    Sapporo, Hokkaido, Japan
  • Pfizer Investigational Site
    Katougun, Hyogo 673-1462, Japan
  • Pfizer Investigational Site
    Kobe, Hyogo 650 0004, Japan
  • Pfizer Investigational Site
    Nishinomiya, Hyogo 662-0838, Japan
  • Pfizer Investigational Site
    Sagamihara-shi, Kanagawa, Japan
  • Pfizer Investigational Site
    Yokohama-shi, Kanagawa, Japan
  • Pfizer Investigational Site
    Yokohama, Kanagawa, Japan
  • Pfizer Investigational Site
    Hatogaya-shi, Saitama, Japan
  • Pfizer Investigational Site
    Kumagaya-shi, Saitama 3600012, Japan
  • Pfizer Investigational Site
    Kumagayashi, Saitama 3600854, Japan
  • Pfizer Investigational Site
    Minamisaitama-gun, Saitama, Japan
  • Pfizer Investigational Site
    Saitama-shi, Saitama, Japan
  • Pfizer Investigational Site
    Tokorozawa, Saitama, Japan
  • Pfizer Investigational Site
    Adachi-Ku, Tokyo, Japan
  • Pfizer Investigational Site
    Bunkyou-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Edogawa-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Itabashi-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Koito-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Meguro-Ku, Tokyo, Japan
  • Pfizer Investigational Site
    Nakano-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Nerima-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Ota-Ku, Tokyo 145-0066, Japan
  • Pfizer Investigational Site
    Ota-Ku, Tokyo, Japan
  • Pfizer Investigational Site
    Setagaya-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Shibuya-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Shinagawa-ku, Tokyo 140-0001, Japan
  • Pfizer Investigational Site
    Shinjyuku-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Suginami-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Sumida-ku, Tokyo 131-0043, Japan
  • Pfizer Investigational Site
    Toyoshima-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Chiba, 266-0031, Japan
  • Pfizer Investigational Site
    Fukuoka, 810-0004, Japan
  • Pfizer Investigational Site
    Fukuoka, Japan
  • Pfizer Investigational Site
    Tokyo, 140-0011, Japan
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00141154
Responsible party
Sponsor
First posted
Sep 1, 2005
Start date
Oct 2004
Last update
Mar 3, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Celecoxib · Loxoprofen

Start the discussion